Hans van Houte
Director of Finance/CFO bei NURIX THERAPEUTICS, INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Hans van Houte is currently the Chief Financial Officer at Nurix Therapeutics, Inc. He previously held positions as the Chief Accounting Officer, Treasurer & Controller at Vertex Pharmaceuticals, Inc., Vice President-Finance & Operations at Emergent Product Development Seattle, Chief Financial Officer at Igenica Biotherapeutics, Inc., and Managing Partner at Bionation LLC.
Mr. van Houte completed his undergraduate degree at Babson College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NURIX THERAPEUTICS, INC.
0,14% | 21.03.2024 | 68 333 ( 0,14% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Hans van Houte
| Unternehmen | Position | Beginn |
|---|---|---|
| NURIX THERAPEUTICS, INC. | Director of Finance/CFO | 01.03.2016 |
Ehemalige bekannte Positionen von Hans van Houte
| Unternehmen | Position | Ende |
|---|---|---|
Emergent Product Development Seattle
 Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Director of Finance/CFO | - |
| Bionation LLC | Corporate Officer/Principal | - |
| VERTEX PHARMACEUTICALS INCORPORATED | Comptroller/Controller/Auditor | - |
Ausbildung von Hans van Houte
| Babson College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| NURIX THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Health Technology |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
| Bionation LLC |
